[eDisclosure Catches the Eye] KOSPI - 19th
[Asia Economy Reporter Ji Yeon-jin]
▲HanAll Biopharma = Submission of clinical trial protocol for Phase 3 clinical trial in Japan for HL161 (generic name Batoclimab), an antibody drug for autoimmune disease treatment, targeting myasthenia gravis
▲AK Holdings = Regarding reports on the issuance of exchangeable bonds, various options are being reviewed, but nothing has been finalized yet.
▲Jeju Air = Regarding reports on the shareholder allocation rights offering, various measures to improve financial structure are being reviewed, but nothing has been specifically decided yet.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- [Breaking] Park Sukeun, Central Labor Relations Commission Chair: "Some Gaps Narrowed Between Samsung Electronics Labor and Management"
- Is This the Peak? As Others Hesitate..."The Answer Is Clear for Surviving the KOSPI 10,000 Era"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
▲Hanwha General Insurance = Decision to proceed with a third-party allotment rights offering worth 175 billion KRW
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
